Pfizer and Moderna See Stocks Drop Despite Pipeline Success as COVID Vaccine Demand Declines
-
Pfizer's stock is down 34% over the past year despite record revenue from its COVID vaccine and treatment. It faces loss of exclusivity for some top-selling drugs.
-
However, Pfizer is transitioning with new drug approvals, its acquisition of Seagen to expand in oncology, and potential for 8+ blockbusters.
-
Moderna's stock has dropped 35% over the past year as COVID vaccine demand declined.
-
But Moderna expects to return to growth in 2025 based on upcoming launch of its RSV vaccine mRNA-1345.
-
It also has several other promising pipeline programs in flu, a flu/COVID combo vaccine, CMV, and cancer vaccines.